CARE(CARE)
CARE
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E | FY2029E |
|---|---|---|---|---|
| Revenue Avg | $258M | $202M | $180M | $163M |
| Low | $255M | $199M | $178M | $161M |
| High | $261M | $204M | $182M | $165M |
| EBITDA Avg | $60M | $47M | $42M | $38M |
| Low | $59M | $46M | $41M | $37M |
| High | $60M | $47M | $42M | $38M |
| EBIT Avg | $51M | $40M | $36M | $32M |
| Low | $51M | $40M | $35M | $32M |
| High | $52M | $41M | $36M | $33M |
| Net Income Avg | $144M | $58M | $72M | $69M |
| Low | $144M | $57M | $71M | $68M |
| High | $145M | $59M | $73M | $71M |
| EPS Avg | $6.43 | $2.57 | $3.22 | $3.09 |
| Low | $6.39 | $2.52 | $3.17 | $3.04 |
| High | $6.45 | $2.62 | $3.27 | $3.14 |
| Analysts (Rev / EPS) | 1 / 2 | 1 / 3 | 1 / 1 | 1 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $47M | $49M | $49M | $50M | $51M | $52M |
| Low | $46M | $48M | $48M | $50M | $51M | $52M |
| High | $47M | $49M | $49M | $50M | $52M | $53M |
| EBITDA Avg | $11M | $11M | $11M | $12M | $12M | $12M |
| Low | $11M | $11M | $11M | $11M | $12M | $12M |
| High | $11M | $11M | $11M | $12M | $12M | $12M |
| EBIT Avg | $9M | $10M | $10M | $10M | $10M | $10M |
| Low | $9M | $10M | $10M | $10M | $10M | $10M |
| High | $9M | $10M | $10M | $10M | $10M | $10M |
| Net Income Avg | $11M | $12M | $13M | $14M | $15M | $15M |
| Low | $11M | $12M | $13M | $14M | $15M | $15M |
| High | $12M | $12M | $13M | $14M | $15M | $15M |
| EPS Avg | $0.52 | $0.56 | $0.58 | $0.62 | $0.67 | $0.68 |
| Low | $0.51 | $0.56 | $0.58 | $0.62 | $0.67 | $0.67 |
| High | $0.53 | $0.57 | $0.59 | $0.63 | $0.68 | $0.69 |
| Analysts (Rev / EPS) | 1 / 2 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |